Jonathan Kabakoff

Purpose-Built Platform for Human Metalloenzyme-Targeted Medicines

Ubiq is an application-layer encryption API that enables development, security, and compliance teams to rapidly integrate application-layer encryption w/ fully integrated key management into any application in minutes. And empowers teams reduce the risk of data theft, free up precious resources, and build compliant and secure-by-design applications.

Cardea Bio is the world’s only mass producer of biocompatible semiconductors, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. In May 2023, Cardea Bio became part of Paragraf, who has revolutionized graphene electronic device manufacturing with its pioneering scalable approach, making it the world's first company to achieve this feat. The acquisition of Cardea Bio and creation of Paragraf USA will enable Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use.

Ubiq is an application-layer encryption API that enables development, security, and compliance teams to rapidly integrate application-layer encryption w/ fully integrated key management into any application in minutes. And empowers teams reduce the risk of data theft, free up precious resources, and build compliant and secure-by-design applications.

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented Fully Enzymatic Synthesis (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of Molecular Assemblies, Inc.

Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. We are a publicly traded life science technology company that is leveraging novel, next-generation sequencing (NGS) and multi-omics technologies to build products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. We are committed to unlocking the potential of our core technologies to reshape the future of genomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact in a rapidly expanding company. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.

Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases. Our most advanced programs target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis (NASH), a liver disease that affects 17 million people in the U.S. and is characterized by excess liver fat, inflammation and fibrosis. We believe that potency and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds, and have selected two oral FXR candidates from a unique chemical scaffold, MET409 and MET642. With our platform, we believe we can develop differentiated FXR agonist therapies for liver and GI diseases.

Purpose-Built Platform for Human Metalloenzyme-Targeted Medicines

Ubiq is an application-layer encryption API that enables development, security, and compliance teams to rapidly integrate application-layer encryption w/ fully integrated key management into any application in minutes. And empowers teams reduce the risk of data theft, free up precious resources, and build compliant and secure-by-design applications.

Cardea Bio is the world’s only mass producer of biocompatible semiconductors, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. In May 2023, Cardea Bio became part of Paragraf, who has revolutionized graphene electronic device manufacturing with its pioneering scalable approach, making it the world's first company to achieve this feat. The acquisition of Cardea Bio and creation of Paragraf USA will enable Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use.

Ubiq is an application-layer encryption API that enables development, security, and compliance teams to rapidly integrate application-layer encryption w/ fully integrated key management into any application in minutes. And empowers teams reduce the risk of data theft, free up precious resources, and build compliant and secure-by-design applications.

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented Fully Enzymatic Synthesis (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of Molecular Assemblies, Inc.